A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT07281937

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Verdiva Bio Dev Limited (from the registry)
Registry
  • NCT NCT07281937
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07281937. Randomized; triple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-07-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Acronym
EVOLVE-2
Condition
Obesity
Condition
Overweight
Intervention (Drug)
VRB-101
Intervention (Drug)
Placebo
Lead sponsor
Verdiva Bio Dev Limited (class: industry)

Record details

Record id
cardio:ct-nct07281937
Content hash
b5a241370f480654889d46c37caa54cda2d493cf94db6b361367fc286387f08a